Nyxoah SA
NYXH Healthcare Medical Instruments & Supplies
Nyxoah SA’s revenue for fiscal 2025 (year ended December 2025) was $11.3 million, up 131.7% from fiscal 2024. In the quarter to June 2026, revenue grew 486.6%, EPS fell 6.35%, free cash flow grew 4.01% and total debt rose 185.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow NYXH
Nyxoah SA (NYXH) EV/Sales
As of 16 October 2026, Nyxoah SA (NYXH) trades at a EV/Sales of 0.7×. Over the past ten years it has ranged from 0.0× (March 2022) to 258× (March 2022); the current reading is higher than 17% of that period. That is below the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 14.8× | (62.44%) |
| FY2024 | 39.4× | 124.34% |
| FY2023 | 17.6× | 17.85% |
| FY2022 | 14.9× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.1× | (73.42%) |
| Mar 2026 | 7.8× | (47.50%) |
| Dec 2025 | 14.8× | (46.43%) |
| Sep 2025 | 27.6× | (41.84%) |
| 17 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DXR Daxor Corporation compare | −14.4× |
| MBOT Microbot Medical Inc. compare | −2.9× |
| NYXH Nyxoah SA | 0.7× |
| OSUR OraSure Technologies, Inc. compare | 0.8× |
| PDEX Pro-Dex, Inc. compare | 2.5× |
| KRMD KORU Medical Systems, Inc. compare | 2.9× |
| STXS Stereotaxis Inc. compare | 3.1× |
| UTMD Utah Medical Products, Inc. compare | 4.2× |
| ZTEKF Zentek Ltd. compare | 288× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)